Antares Pharma, Inc. announced that the U.S. Food and Drug Administration has approved TLANDO (testosterone undecanoate), an oral treatment for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. Lipocine licensed the exclusive U.S. commercialization rights for TLANDO to Antares Pharma.
Antares Pharma, Inc.
Equities
ATRS
US0366421065
Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | |
---|---|---|
-5.56% | 18TCr | |
-0.11% | 11TCr | |
-6.17% | 6.61TCr | |
+2.64% | 5.07TCr | |
+6.58% | 4.31TCr | |
+4.91% | 4.13TCr | |
+21.98% | 3.16TCr | |
+14.45% | 2.5TCr | |
-5.81% | 2.42TCr |